ASH 2017 | CAR T-cell development in Europe – where are we in CLL?

John Gribben

John Gribben, MD, from Barts Cancer Institute, London, gives us an update on CAR-T cell therapy development in Europe during the ASH 2017 meeting in Atlanta, GA. Europe is behind the US and Professor Gribben has typically been sending his patients to the US for enrolment in trials. He tells us where we are in terms of CLL compared with ALL and lymphoma, specifically for patients with Richter’s, who are in great need of new treatments.

Share this video